A Phase I Study Evaluating the Efficacy and Toxicity of Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer

Inclusion Criteria:

- Patients must have persistent, metastatic, or recurrent platinum resistant or
refractory ovarian or primary peritoneal cancer.

- No restriction on previous treatment regimens, but patients must be at least 2 weeks
out from last chemotherapy or investigational agent.

- Patients must be >= 18.

- Patients must have a life expectancy of at least 6 months.

- Patients must have KPS >= 60.

- Patients must have acceptable organ and marrow function as defined below (within 2
weeks prior to radiotherapy):

- leukocytes >=3,000/uL

- absolute neutrophil count >=1,500uL

- platelets >=100,000/uL

- total bilirubin within 1.5X normal institutional limits

- AST(SGOT)/ALT(SGPT) <2.5 X institutional upper limit of normal

- creatinine within normal institutional limits OR

- creatinine clearance >=60 mL/min/1.73 m^2 for patients with creatinine levels
above institutional normal

- Patients must be willing to undergo a pre- and post-treatment FDG-PET/CT.

- Ability to understand and the willingness to sign a written informed consent
document.

Exclusion Criteria:

- Patients should not have received radiation overlapping with the proposed treatment
field.

- Patients cannot be receiving chemotherapy or other investigation agents from two
weeks prior to radiation through undergoing their post-therapy FDG-PET/CT

- Patients cannot be pregnant or nursing.

- Patients cannot have disease >= 8cm or greater than 3 regions of disease.

- Patients cannot have concurrent malignancy other than non-melanoma skin cancer,
non-invasive bladder cancer, or carcinoma in situ of the cervix.